©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessUsher syndrome type 1 + 2 + 3, differential diagnosis

Summary

Short information

Comprehensive differential diagnostic panel for Usher syndrome type 1-3 containing 11 guideline-curated core or core candidate genes and altogether 24 curated genes according to the clinical signs

ID
UP0010
Number of genes
16 Accredited laboratory test
Examined sequence length
65,7 kb (Core-/Core-canditate-Genes)
81,3 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Test material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
ADGRV118921NM_032119.4AR, digenisch
CDH2310065NM_022124.6AR, digenisch
CIB2564NM_006383.4AR
CLRN1699NM_174878.3AR
HARS11530NM_002109.6AR
MYO7A6648NM_000260.4AR
PCDH155868NM_033056.4AR, digenisch
USH1C1659NM_005709.4AR
USH1G1386NM_173477.5AR
USH2A15609NM_206933.4AR
WHRN2724NM_015404.4AR
ABHD121197NM_001042472.3AR
CEP2507329NM_007186.6AR
PDZD73102NM_001195263.2AR
PEX62943NM_000287.4AR, AD
PRPS1957NM_002764.4XL

Informations about the disease

Clinical Comment

Usher syndrome, USH, is characterized by partial or complete sensorineural hearing loss and retinitis pigmentosa, whereby both neurologic components worsen over time. Loss of night vision sets in first, followed by blind spots that develop in the peripheral visual field. In some cases, the vision is further impaired by cataract. Many people with retinitis pigmentosa retain some central vision throughout their lives. USH has been clinically classified into three types, which are distinguished by the severity of hearing loss, the presence or absence of balance problems and age at onset. These types are sometimes further subdivided into subtypes based on genetic causes. Yet, because USH (and likewise some differential-diagnostically related syndromes) represent a clinical disease continuum, the three USH types are discussed here collectively. Most people with USH1 are born with severe to profound hearing loss. Worsening of visual impairment becomes evident in childhood. USH1 also causes abnormalities of the vestibular system leading to balance problems. USH2 is characterized by hearing loss from birth and progressive vision loss that begins somewhat later in adolescence or adulthood. The hearing loss associated with this form ranges from mild to severe and primarily affects the ability to hear high-frequency sounds. Unlike the other forms, USH2 is not associated with vestibular abnormalities. Patients with USH3 suffer from hearing and visual impairments that begin later in life. USH3 is usually associated with normal hearing at birth. Hearing loss typically begins in late childhood or adolescence, after language development, and becomes more severe over time. By middle age, most affected individuals have profound hearing loss. The impaired vision caused by retinitis pigmentosa also develops in late childhood or adolescence. Some affected individuals develop abnormalities of the vestibular organ.

USH can be caused by mutations in a number of different genes. Mutations in at least six genes cause USH1; mutations in MYO7A are most common, followed by mutations in the CDH23 gene. USH2 is caused by mutations in three genes; most cases of are due to pathogenic variants in the USH2A gene. Digenic USH2 is due to mutations in ADGRV1 and PDZD7. USH3 is most commonly caused by mutations in the CLRN1 gene. Virtually all types of USH are inherited in an autosomal recessive manner. The molecular genetic yield in USH is high but incomplete (~90%). Therefore, a negative DNA test result does not exclude the clinical diagnosis.

References: https://www.ncbi.nlm.nih.gov/books/NBK1265/

https://www.ncbi.nlm.nih.gov/books/NBK1341/

 

Synonyms
  • Alias: Retinitis pigmentosa + congenital deafness
  • Alias: Retinitis pigmentosa-deafness syndrome
  • Allelic: Cataract 41 (WFS1)
  • Allelic: Charcot-Marie-Tooth disease, XLR, 5 (PRPS1)
  • Allelic: Charcot-Marie-Tooth disease, axonal, type 2W (HARS1)
  • Allelic: Deafness, AD (MYO7A)
  • Allelic: Deafness, AR 12 (CDH23)
  • Allelic: Deafness, AR 18A (USH1C)
  • Allelic: Deafness, AR 2 (MYO7A)
  • Allelic: Deafness, AR 31 (WHRN)
  • Allelic: Deafness, AR 48 (CIB2)
  • Allelic: Deafness, AR 57 (ADGRV1)
  • Allelic: Diabetes mellitus, noninsulin-dependent, association with (WFS1)
  • Allelic: Febrile seizures, familial, 4 (ADGRV1)
  • Allelic: Gout, PRPS-related (PRPS1)
  • Allelic: Macular degeneration, XL atrophic (RPGR)
  • Allelic: Phosphoribosylpyrophosphate synthetase superactivity (PRPS1)
  • Allelic: Pituitary adenoma 5, multiple types (CDH23)
  • Allelic: Retinitis pigmentosa 39 (USH2)
  • Allelic: Retinitis pigmentosa 61 (CLRN1)
  • Alport syndrome 1, XL (COL4A5)
  • Alstrom syndrome (ALMS1)
  • Arts syndrome (PRPS1)
  • Cone-rod dystrophy + hearing loss 2 (CEP250)
  • Cone-rod dystrophy and hearing loss (CEP78)
  • Cone-rod dystrophy, XL, 1 (RPGR)
  • Deafness, AD 6/14/38 (WFS1)
  • Deafness, XL 1 (PRPS1)
  • Heimler syndrome 1 (PEX1)
  • Mohr-Tranebjaerg syndrome (TIMM8A)
  • Peroxisome biogenesis disorder 1A, Zellweger, + 1B, NALD/IRD (PEX1)
  • Retinal disease in Usher syndrome type 2A, modifier of (ADGRV1)
  • Retinitis pigmentosa 3 (RPGR)
  • Retinitis pigmentosa, XL, + sinorespiratory infections, +/- deafness (RPGR)
  • Usher syndrome, type 1B (MYO7A)
  • Usher syndrome, type 1C (USH1C)
  • Usher syndrome, type 1D (CDH23)
  • Usher syndrome, type 1D/F Dig (CDH23/PCDH15)
  • Usher syndrome, type 1F (PCDH15)
  • Usher syndrome, type 1G (USH1G)
  • Usher syndrome, type 1J (CIB2)
  • Usher syndrome, type 2A (USH2A)
  • Usher syndrome, type 2C (ADGRV1)
  • Usher syndrome, type 2C (ADGRV1/PDZD7 Dig)
  • Usher syndrome, type 2D (WHRN)
  • Usher syndrome, type 3A (CLRN1)
  • Usher syndrome, type 3B (HARS1)
  • Wolfram syndrome 1 (WFS1)
  • Wolfram syndrome 2 (CISD2)
  • Wolfram-like syndrome, AD (WFS1)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • digenisch
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

Test-Stärken

  • DAkkS-akkreditiertes Labor
  • EU-Richtlinie für IVD in Umsetzung
  • Qualitäts-kontrolliert arbeitendes Personal
  • Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
  • Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
  • eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
  • unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
  • unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
  • unsere umfassenden klinischen Aussagen

Testeinschränkungen

  • Gene mit eingeschränkter Abdeckung werden gekennzeichnet
  • Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
  • es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
  • die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
  • Gen-Konversionen
  • komplexe Inversionen
  • Balancierte Translokationen
  • Mitochondriale Varianten
  • Repeat-Expansionen, sofern nicht anders dokumentiert
  • nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
  • niedriger Mosaik-Status
  • Repeat-Blöcke von Mononukleotiden
  • Indels >50bp (Insertionen-Deletionen)
  • Deletionen oder Duplikationen einzelner Exons
  • Varianten innerhalb von Pseudogenen
  • die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde

Laboratory requirement

  • Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.

  • Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.

  • Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.

  • Die Untersuchung wird auch für Selbstzahler angeboten.